Chromomycin A2 potently inhibits glucosestimulated insulin secretion from pancreatic β cells

Michael A. Kalwat, In Hyun Hwang, Jocelyn Macho, Magdalena G. Grzemska, Jonathan Z. Yang, Kathleen McGlynn, John B MacMillan, Melanie H Cobb

Research output: Contribution to journalArticle

Abstract

Modulators of insulin secretion could be used to treat diabetes and as tools to investigate β cell regulatory pathways in order to increase our understanding of pancreatic islet function. Toward this goal, we previously used an insulin-linked luciferase that is cosecreted with insulin in MIN6 β cells to perform a high-throughput screen of natural products for chronic effects on glucose-stimulated insulin secretion. In this study, using multiple phenotypic analyses, we found that one of the top natural product hits, chromomycin A2 (CMA2), potently inhibited insulin secretion by at least three potential mechanisms: disruption of Wnt signaling, interference of β cell gene expression, and partial suppression of Ca2+ influx. Chronic treatment with CMA2 largely ablated glucose-stimulated insulin secretion even after washout, but it did not inhibit glucose-stimulated generation of ATP or Ca2+ influx. However, by using the KATP channel opener diazoxide, we uncovered defects in depolarization-induced Ca2+ influx that may contribute to the suppressed secretory response. Glucose-responsive ERK1/2 and S6 phosphorylation were also disrupted by chronic CMA2 treatment. By querying the FUS ION bioinformatic database, we revealed that the phenotypic effects of CMA2 cluster with a number of Wnt-GSK3 pathway-related genes. Furthermore, CMA2 consistently decreased GSK3β phosphorylation and suppressed activation of a β-catenin activity reporter. CMA2 and a related compound, mithramycin, are known to have DNA interaction properties, possibly abrogating transcription factor binding to critical β cell gene promoters. We observed that CMA2 but not mithramycin suppressed expression of PDX1 and UCN3. However, neither expression of INSI/II nor insulin content was affected by chronic CMA2. The mechanisms of CMA2-induced insulin secretion defects may involve components both proximal and distal to Ca2+ influx. Therefore, CMA2 is an example of a chemical that can simultaneously disrupt β cell function through both noncytotoxic and cytotoxic mechanisms. Future therapeutic applications of CMA2 and similar aureolic acid analogues should consider their potential effects on pancreatic islet function.

Original languageEnglish (US)
Pages (from-to)1747-1757
Number of pages11
JournalJournal of General Physiology
Volume150
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Insulin
Plicamycin
Glucose
Biological Products
Islets of Langerhans
chromomycin A2
Phosphorylation
Diazoxide
S 6
Catenins
KATP Channels
Wnt Signaling Pathway
Computational Biology
Luciferases
Genes
Transcription Factors
Adenosine Triphosphate
Databases
Gene Expression
DNA

ASJC Scopus subject areas

  • Physiology

Cite this

Chromomycin A2 potently inhibits glucosestimulated insulin secretion from pancreatic β cells. / Kalwat, Michael A.; Hwang, In Hyun; Macho, Jocelyn; Grzemska, Magdalena G.; Yang, Jonathan Z.; McGlynn, Kathleen; MacMillan, John B; Cobb, Melanie H.

In: Journal of General Physiology, Vol. 150, No. 12, 01.12.2018, p. 1747-1757.

Research output: Contribution to journalArticle

Kalwat, Michael A. ; Hwang, In Hyun ; Macho, Jocelyn ; Grzemska, Magdalena G. ; Yang, Jonathan Z. ; McGlynn, Kathleen ; MacMillan, John B ; Cobb, Melanie H. / Chromomycin A2 potently inhibits glucosestimulated insulin secretion from pancreatic β cells. In: Journal of General Physiology. 2018 ; Vol. 150, No. 12. pp. 1747-1757.
@article{e0f293604ecd47048c11f59ad10f8d32,
title = "Chromomycin A2 potently inhibits glucosestimulated insulin secretion from pancreatic β cells",
abstract = "Modulators of insulin secretion could be used to treat diabetes and as tools to investigate β cell regulatory pathways in order to increase our understanding of pancreatic islet function. Toward this goal, we previously used an insulin-linked luciferase that is cosecreted with insulin in MIN6 β cells to perform a high-throughput screen of natural products for chronic effects on glucose-stimulated insulin secretion. In this study, using multiple phenotypic analyses, we found that one of the top natural product hits, chromomycin A2 (CMA2), potently inhibited insulin secretion by at least three potential mechanisms: disruption of Wnt signaling, interference of β cell gene expression, and partial suppression of Ca2+ influx. Chronic treatment with CMA2 largely ablated glucose-stimulated insulin secretion even after washout, but it did not inhibit glucose-stimulated generation of ATP or Ca2+ influx. However, by using the KATP channel opener diazoxide, we uncovered defects in depolarization-induced Ca2+ influx that may contribute to the suppressed secretory response. Glucose-responsive ERK1/2 and S6 phosphorylation were also disrupted by chronic CMA2 treatment. By querying the FUS ION bioinformatic database, we revealed that the phenotypic effects of CMA2 cluster with a number of Wnt-GSK3 pathway-related genes. Furthermore, CMA2 consistently decreased GSK3β phosphorylation and suppressed activation of a β-catenin activity reporter. CMA2 and a related compound, mithramycin, are known to have DNA interaction properties, possibly abrogating transcription factor binding to critical β cell gene promoters. We observed that CMA2 but not mithramycin suppressed expression of PDX1 and UCN3. However, neither expression of INSI/II nor insulin content was affected by chronic CMA2. The mechanisms of CMA2-induced insulin secretion defects may involve components both proximal and distal to Ca2+ influx. Therefore, CMA2 is an example of a chemical that can simultaneously disrupt β cell function through both noncytotoxic and cytotoxic mechanisms. Future therapeutic applications of CMA2 and similar aureolic acid analogues should consider their potential effects on pancreatic islet function.",
author = "Kalwat, {Michael A.} and Hwang, {In Hyun} and Jocelyn Macho and Grzemska, {Magdalena G.} and Yang, {Jonathan Z.} and Kathleen McGlynn and MacMillan, {John B} and Cobb, {Melanie H}",
year = "2018",
month = "12",
day = "1",
doi = "10.1085/jgp.201812177",
language = "English (US)",
volume = "150",
pages = "1747--1757",
journal = "Journal of General Physiology",
issn = "0022-1295",
publisher = "Rockefeller University Press",
number = "12",

}

TY - JOUR

T1 - Chromomycin A2 potently inhibits glucosestimulated insulin secretion from pancreatic β cells

AU - Kalwat, Michael A.

AU - Hwang, In Hyun

AU - Macho, Jocelyn

AU - Grzemska, Magdalena G.

AU - Yang, Jonathan Z.

AU - McGlynn, Kathleen

AU - MacMillan, John B

AU - Cobb, Melanie H

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Modulators of insulin secretion could be used to treat diabetes and as tools to investigate β cell regulatory pathways in order to increase our understanding of pancreatic islet function. Toward this goal, we previously used an insulin-linked luciferase that is cosecreted with insulin in MIN6 β cells to perform a high-throughput screen of natural products for chronic effects on glucose-stimulated insulin secretion. In this study, using multiple phenotypic analyses, we found that one of the top natural product hits, chromomycin A2 (CMA2), potently inhibited insulin secretion by at least three potential mechanisms: disruption of Wnt signaling, interference of β cell gene expression, and partial suppression of Ca2+ influx. Chronic treatment with CMA2 largely ablated glucose-stimulated insulin secretion even after washout, but it did not inhibit glucose-stimulated generation of ATP or Ca2+ influx. However, by using the KATP channel opener diazoxide, we uncovered defects in depolarization-induced Ca2+ influx that may contribute to the suppressed secretory response. Glucose-responsive ERK1/2 and S6 phosphorylation were also disrupted by chronic CMA2 treatment. By querying the FUS ION bioinformatic database, we revealed that the phenotypic effects of CMA2 cluster with a number of Wnt-GSK3 pathway-related genes. Furthermore, CMA2 consistently decreased GSK3β phosphorylation and suppressed activation of a β-catenin activity reporter. CMA2 and a related compound, mithramycin, are known to have DNA interaction properties, possibly abrogating transcription factor binding to critical β cell gene promoters. We observed that CMA2 but not mithramycin suppressed expression of PDX1 and UCN3. However, neither expression of INSI/II nor insulin content was affected by chronic CMA2. The mechanisms of CMA2-induced insulin secretion defects may involve components both proximal and distal to Ca2+ influx. Therefore, CMA2 is an example of a chemical that can simultaneously disrupt β cell function through both noncytotoxic and cytotoxic mechanisms. Future therapeutic applications of CMA2 and similar aureolic acid analogues should consider their potential effects on pancreatic islet function.

AB - Modulators of insulin secretion could be used to treat diabetes and as tools to investigate β cell regulatory pathways in order to increase our understanding of pancreatic islet function. Toward this goal, we previously used an insulin-linked luciferase that is cosecreted with insulin in MIN6 β cells to perform a high-throughput screen of natural products for chronic effects on glucose-stimulated insulin secretion. In this study, using multiple phenotypic analyses, we found that one of the top natural product hits, chromomycin A2 (CMA2), potently inhibited insulin secretion by at least three potential mechanisms: disruption of Wnt signaling, interference of β cell gene expression, and partial suppression of Ca2+ influx. Chronic treatment with CMA2 largely ablated glucose-stimulated insulin secretion even after washout, but it did not inhibit glucose-stimulated generation of ATP or Ca2+ influx. However, by using the KATP channel opener diazoxide, we uncovered defects in depolarization-induced Ca2+ influx that may contribute to the suppressed secretory response. Glucose-responsive ERK1/2 and S6 phosphorylation were also disrupted by chronic CMA2 treatment. By querying the FUS ION bioinformatic database, we revealed that the phenotypic effects of CMA2 cluster with a number of Wnt-GSK3 pathway-related genes. Furthermore, CMA2 consistently decreased GSK3β phosphorylation and suppressed activation of a β-catenin activity reporter. CMA2 and a related compound, mithramycin, are known to have DNA interaction properties, possibly abrogating transcription factor binding to critical β cell gene promoters. We observed that CMA2 but not mithramycin suppressed expression of PDX1 and UCN3. However, neither expression of INSI/II nor insulin content was affected by chronic CMA2. The mechanisms of CMA2-induced insulin secretion defects may involve components both proximal and distal to Ca2+ influx. Therefore, CMA2 is an example of a chemical that can simultaneously disrupt β cell function through both noncytotoxic and cytotoxic mechanisms. Future therapeutic applications of CMA2 and similar aureolic acid analogues should consider their potential effects on pancreatic islet function.

UR - http://www.scopus.com/inward/record.url?scp=85057755548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057755548&partnerID=8YFLogxK

U2 - 10.1085/jgp.201812177

DO - 10.1085/jgp.201812177

M3 - Article

VL - 150

SP - 1747

EP - 1757

JO - Journal of General Physiology

JF - Journal of General Physiology

SN - 0022-1295

IS - 12

ER -